Might <b>β</b>3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?

Jeffrey S. Flier

doi:10.1172/JCI136476

Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?

Department of Medicine and Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA.

Address correspondence to: Jeffrey S. Flier, 220 Longwood Ave., Goldenson 542, Boston, Massachusetts 02115, USA. Phone: 617.432.1501; Email: Jeffrey_flier@hms.harvard.edu.

Find articles by Flier, J. in: JCI | PubMed | Google Scholar

First published March 23, 2020 - More info

J Clin Invest. https://doi.org/10.1172/JCI136476.
© 2020 American Society for Clinical Investigation

First published March 23, 2020 - Version history

Brown and beige adipose tissues contain thermogenic fat cells that can be activated by β3-adrenergic receptor agonists. In rodents, such drugs both diminish obesity and improve glucose homeostasis. In this issue of the JCI, O’Mara et al. and Finlin and Memetimin et al. report that chronic administration of the approved β3 agonist mirabegron to human subjects was without effect on body weight or fat mass, but improved several measures of glucose homeostasis. Though the mechanisms mediating these metabolic effects are uncertain, the data suggest that β3 agonists could have therapeutic utility in disorders of glucose homeostasis.

Preview pages

Reset

Next Page 0 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.